The present invention encompasses compounds and methods for treating urinary tract infections.

Hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), and compositions thereof, are useful as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.

##STR00001##

New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits. ##STR00001##

New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits. ##STR00001##

The present invention encompasses compounds and methods for treating urinary tract infections.

The present invention encompasses compounds and methods for treating urinary tract infections.

Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.

Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.

The present invention provides modified sophorolipids that can eliminate existing foam and/or prevent the formation of new foam. The modifications including peracetylation and/or global transformation of sophorose hydroxyl groups of sophorolipids to ethers to reduce the HLB value and create biobased defoamers with high biobased carbon content. The present invention also provides compositions comprising modified sophorolipids and methods of using such compositions for inhibiting and/or reducing foam formation.

The present invention provides modified sophorolipids that can eliminate existing foam and/or prevent the formation of new foam. The modifications including peracetylation and/or global transformation of sophorose hydroxyl groups of sophorolipids to ethers to reduce the HLB value and create biobased defoamers with high biobased carbon content. The present invention also provides compositions comprising modified sophorolipids and methods of using such compositions for inhibiting and/or reducing foam formation.